Business Wire

Sonar to Improve the Quality of AI-Generated Code, Provide Automated Fix Recommendations

3.10.2024 16:00:00 EEST | Business Wire | Press release

Share

Sonar, the leading Clean Code solution provider, today announced two new product capabilities for today’s AI-driven software development ecosystem. These new capabilities are designed to support better software development in two critical and distinct ways – Sonar AI Code Assurance and Sonar AI CodeFix improve the quality of code produced by generative AI and enhance Sonar’s offering with AI to deliver a better developer experience, respectively. Both capabilities deepen Sonar’s commitment to the delivery of high-quality, secure code and increasing developer productivity.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241003439224/en/

Sonar introduces AI Code Assurance and AI CodeFix to improve the quality of code produced by generative AI. (Photo: Business Wire)

AI Code Assurance helps organizations ensure the quality of AI-generated code by thoroughly analyzing the codebase for issues, ensuring that projects using AI tools to generate code meet high standards of quality and security. Today, bad code is already estimated to cost businesses more than a trillion dollars, making it critical for AI-generated code, which promises to increase the volume of code written, to be comprehensively checked for quality and security issues.

“AI is transforming the way developers work, streamlining processes, and reducing the toil associated with writing code. As the adoption of AI coding assistants grows, however, we are seeing a new issue emerge: code accountability. AI-generated code needs review by developers, but accountability for doing this is increasingly diluted. As a result, we’re seeing the review step frequently being shortchanged,” said Tariq Shaukat, CEO of Sonar. “With AI Code Assurance, we’re helping organizations ensure that AI written code receives the high level of quality and security review that you would expect from your developers.”

AI CodeFix allows developers to seamlessly resolve issues detected by Sonar's code analysis engine with a single click, directly within their workflow. The AI-powered fix recommendations help streamline developer workflows, speed up issue remediation, and improve the developer experience. As leading research has established, developer experience improves with the automation that AI provides. For example, McKinsey reported that developers using generative AI tools in their work stream are “twice as likely to report overall happiness, fulfillment, and a state of flow” than those who aren’t.

“AI CodeFix helps developers streamline their workflow and ramp up their productivity. Rather than switching between solutions or manual efforts, we’re putting remediation options for Sonar-identified issues right in front of the people working on them – and giving them the ability to fix the issues in an instant. We’re excited to see how our users adopt this capability and better understand how we can further integrate AI into our solutions to improve the developer experience,” said Fabrice Bellingard, VP of Product at Sonar.

The features are currently available for both SonarQube and SonarCloud.

AI Code Assurance for Confidence in Code Quality

With AI Code Assurance for SonarQube and SonarCloud, developers can be confident that their AI-generated code is clean and secure. By implementing the Sonar AI Code Assurance workflow, organizations have the assurance that all code (AI-generated and human-developed) has been thoroughly scanned for issues and that projects leveraging AI tools are meeting high standards of quality and security.

AI Code Assurance capabilities include:

  • Project Tagging: Developers can easily tag projects that contain AI-generated code, initiating a comprehensive analysis through the Sonar AI Code Assurance workflow.
  • Quality Gate Enforcement: An optimized quality gate for AI-generated code ensures that only code meeting strict quality and security standards is approved for production.
  • AI Code Assurance Approved Badge: Projects that pass the quality gate receive a badge signifying that the code has gone through a rigorous AI-ready analysis.

AI CodeFix for Fast Issue Remediation

Fast-paced software development environments require solutions that enhance productivity, reduce time-to-market, and maintain high code quality. Today, millions of Sonar users can detect and fix issues in their code leveraging Sonar’s database of code rules and best practices. Now, at the click of a button, developers can use AI CodeFix to automatically generate solutions to issues in the same SonarQube and SonarCloud user interface where they review issues.

AI CodeFix capabilities include:

  • Instant Code Fixes: Minimize manual debugging efforts and increase productivity by automatically generating code fix suggestions.
  • Contextual Understanding of Sonar findings: Leverages LLMs to understand code context and provide relevant fixes.
  • Seamless Integration: Developers fix issues directly within their IDE using SonarLint connected mode, ensuring a smooth workflow.
  • Continuous Learning: Ongoing suggestion improvements based on user feedback
  • Multi-Language Support: Supports flagship programming languages such as Java, JS/TS, C#, Python, and C/C++.

AI Code Assurance is now available on SonarQube and will be generally available in SonarCloud by the end of October. AI CodeFix is available for early access in SonarQube Enterprise Edition, SonarQube Data Center Edition, and SonarCloud Team and Enterprise plans.

For more information on the new features, visit our AI features page at https://www.sonarsource.com/solutions/ai/.

About Sonar

Sonar's Clean Code solutions, SonarQube, SonarCloud, and SonarLint, help developers prevent code quality and security issues from ever reaching production. Sonar analyzes all code, regardless of who writes it—your internal team or genAI—resulting in more secure, reliable, and maintainable software. Rooted in the open source community, Sonar’s solutions support over 30 programming languages, frameworks, and infrastructure technologies. Today, Sonar is used by 7M+ developers and 400K organizations worldwide, including the DoD, Microsoft, NASA, MasterCard, Siemens, and T-Mobile.

To learn more about Sonar, please visit: https://www.sonarsource.com/products/all/

View source version on businesswire.com: https://www.businesswire.com/news/home/20241003439224/en/

Contacts

Media
Katie Hyman
Senior PR Manager for Sonar
(707) 291-1469
press@sonarsource.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye